Verona Pharma has announced that it has successfully commenced a Phase I/II clinical trial of RPL554 for the treatment of asthma, a chronic lung condition that inflames and narrows airways. Verona Pharma now has clinical trials of RPL554 in COPD and asthma on-going. RPL554 has demonstrated a very attractive profile, including synergistic effects with current standard therapy, with its combined bronchodilator and anti-inflammatory properties representing a novel approach to the treatment of respi ....
